References
- World Health OrganizationWHO. Schizophrenia [Internet] Available from: http://www.who.int/mental_health/management/schizophrenia/en/Accessed July 21, 2016
- National Institute of Mental HealthSchizophrenia Available from: http://www.nimh.nih.gov/health/statistics/prevalence/schizophrenia.shtmlAccessed July 21, 2016
- MillierASchmidtUAngermeyerMCHumanistic burden in schizophrenia: a literature reviewJ Psychiatr Res201454859324795289
- CarrVJLewinTJNeilALHalpinSAHolmesSPremorbid, psychosocial and clinical predictors of the costs of schizophrenia and other psychosesBr J Psychiatry200418451752515172946
- Ascher-SvanumHZhuBFariesDEThe cost of relapse and the predictors of relapse in the treatment of schizophreniaBMC Psychiatry201010220059765
- CloutierMAigbogunMSGuerinAThe economic burden of schizophrenia in the United States in 2013J Clin Psychiatry201677676477127135986
- American Psychiatric AssociationPractice Guideline for the Treatment of Patients With Schizophrenia2nd edWashington, DCAmerican Psychiatric Association2004
- KishimotoTAgarwalVKishiTLeuchtSKaneJMCorrellCURelapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsMol Psychiatry2013181536622124274
- CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
- HaddadPMBrainCScottJNonadherence with antipsychotic medication in schizophrenia: challenges and management strategiesPatient Relat Outcome Meas20145436225061342
- OlivaresJMSermonJHemelsMSchreinerADefinitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAnn Gen Psychiatry20131213224148707
- KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
- OffordSWongBMirskiDBakerRALinJHealthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oralJ Med Econ201316223123923163287
- AlphsLSchoolerNLaurielloJHow study designs influence comparative effectiveness outcomes: the case of oral versus long-acting injectable antipsychotic treatments for schizophreniaSchizophr Res20141562–322823224842538
- KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
- LafeuilleMHLaliberté-AugerFLefebvrePFroisCFastenauJDuhMSImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisBMC Psychiatry20131322124016390
- LafeuilleMHGrittnerAMFortierJComparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychoticsAm J Health Syst Pharm201572537838925694413
- MarcusSCZummoJPettitARStoddardJDoshiJAAntipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital dischargeJ Manag care Spec Pharm201521975476826308223
- BrnabicAJKelinKAscher-SvanumHMontgomeryWKadziolaZKaragianisJMedication discontinuation with depot and oral antipsychotics in outpatients with schizophrenia: comparison of matched cohorts from a 12-month observational studyInt J Clin Pract201165994595321849009
- ShiLAscher-SvanumHZhuBFariesDMontgomeryWMarderSRCharacteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaPsychiatr Serv200758448248817412849
- ZhuBAscher-SvanumHShiLFariesDMontgomeryWMarderSRTime to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaPsychiatr Serv200859331531718308914
- HaddadPMTaylorMNiazOSFirst-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studiesBr J Psychiatry Suppl200952S20S2819880913
- PierreJMExtrapyramidal symptoms with atypical antipsychotics: incidence, prevention and managementDrug Saf200528319120815733025
- LafeuilleMHGravelJLefebvrePPatterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychoticsJ Med Econ201316111290129924006903
- SunSXLiuGGChristensenDBFuAZReview and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United StatesCurr Med Res Opin200723102305231217697454
- BrissosSVeguillaMRTaylorDBalanzá-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol20144519821925360245
- LafeuilleMHDeanJCarterVSystematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophreniaCurr Med Res Opin20143081643165524730586